Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
|
|
- Elizabeth Grant
- 5 years ago
- Views:
Transcription
1 Published Ahead of Print on May 17, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study by Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brümmendorf, and H. Jean Khoury Haematologica 2018 [Epub ahead of print] Citation: Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong-Wook Kim, Philippe Schafhausen, Rocco Crescenzo, Nathalie Bardy-Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, Liza DeAnnuntis, Tim H. Brümmendorf, and H. Jean Khoury. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study. Haematologica. 2018; 103:xxx doi: /haematol Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
2 ^ d d ' W d : d :, > d, D < d t < d W ^ d Z e E e D ^ e < E e > e > e d, d dd, : < dd d h D D / d h d D, dy h^ d W D d KE d ^ ^ D, ^ ^ < d / D //, t d h,, ' e W / W h^ e W ' Z W & e W / D h^ e W / ' d h^ dd h Ztd, ' dd t / h ' h^ ' W, ^ h D s de ddeddd / W ldeddedddeddd & ldeddedddddde Z > WD> d Eddddedede d W / D : s ^ W, >> d
3 W / : E/ ddeeed ddeede ' W W W D ^ : D ^ E W d D ^ E W :,> D ^ E d W D ^ E,D< W t< D ^ E W D ^ E W D ^ E W^ D ^ E W d, D ^ E W E W,:< D ^ E d W Z E <E > > W D^ W ^ ' W : D^,:< ' W : :,>,D< t< W^ d,,:< ' W : :,>,D< t< W^ D^ d,,:< Z E > <E > ^ ' W : :,>,D< t< W^ D^ d,,:< > t dde D dddd d d d e d Z dd ^ d d
4 ^ W l t d d lded D dd e d e ee d dd e d d ee d d d ddl ddl del del d edl ddl d < D eel eel d edl eel d d del d ddl < D edl d edl d K dee d de d ldd D d K eel del del d d ddl E d d d d Eddddedede d
5 / t Z >d d</ W W l D> d d d d</ ^ d</ W D> & d</ d d</ d d e d</ e e ^ Z >d e e W lw W W D> d</ dddd e d d d WD> dd Z dd Z >d d</ dd d d
6 dd de dd dd, d d WD> md D ^ d d d : ddde dd dd W d W d ddd W d W,Z e Z dd edd md W W d ' W, mde W lwd> /D Z medd /D / K ^ D d
7 ^ dd d md D /^ W / Z ^ & DDZ md Z >d Z W dd < D ^ K ^ D dd d W W WD> dd W W&^ W dd K e
8 K^ < D W K^ d K^ / Edddeddedd ^ md dd E / d s d d d d Z W ded WD> /D Z lded /D / lee K ^ d ^d d dddd K d dddd med d K^ dd e d ekee d dd e d d ee d d d d ddd ddl d ddd ddl /D Z led /D / ldd d lde e
9 d ddd del d de ddl d d K ^ d ^d d d W lde del ldd el led ddl lde el d d d W d W d d K med med ddl ddl el ddl dl el ddl del K ^ d ^d E ddl d /D Z led /D / lde d ddl d ed del D d d d dd D Z ddl led ded ddl lde Z K dde Z ee ddl D Z dd del Z d D Z d del del e
10 Z W Z d dd Z d d d D Z Z edl ldde ded ddl lddd del lddd dde D Z del ldde Z d DDZ ddl led dee d d /D Z /D / DDZ /D Z d d z D Z edl ddl Z med med K ^ d ^d < D d d edl eel D Z eel eel Z eel edl DDZ d d & d K dd dde del D Z de ddd del Z dd ed ddl DDZ & d e D Z dd Z d DDZ edl ldde dde D Z eel ldde Z ddd Z ddd D Z ed Z ddd /D Z led /D / ldd ddd ed edl /D Z edl /D / del D Z ee ddd edl Z K ^ d ^d & ddl D Z de ddl D Z e
11 d dl D Z dd /D Z ldd /D / lde ddd de del /D Z eel /D / del D Z dd dd del Z d ddl D Z e del D Z ddd d dl D Z D Z < D ddd ddd dee de D Z < D ded ded K ^ d ^d K ddd eel ee ddl d Z >d /D Z /D Z led dde del /D / le ee el K ^ d ^d d /D Z dd Z >d &ddes le Ddddd le Dddds le 'ddd le dddd/ le dddd/ dd ee edl D Z ed ddd del e dd ddl ldd ldd ldd & d D Z eel del ddl Z del ddl ddl dd
12 ldd ldd D Z edl edl Z ddl del K ddd del Z >d de d dddd/ le sdee> ld Dddds ld dd de Z >d & dd W ldd le d ld ld ld & W Z e Z dd,z d d K W WD> dd /D Z ldd /D / ld e W /D Z le /D / ld e W /D Z d d dl /D Z el /D / dl edl Wld dddd W d md dd
13 dd e dde d W ddd d d /D Z W edd dded dd d D Z d Z d,z d W dl d del /D Z ddl /D / ddl d ddl /D Z del /D / el ddl W d > K ^ d ^d < D K^ d edl /D Z edl /D / edl edl /D Z eel /D / eel d ddl d ddl & d dd del dd d d d dd dd W med K^ med edl eel K ^ d ^d W lde del /D Z ldd /D / ld lde del /D Z ldd /D / ld ld el /D / E dd & dd d /D Z d d d d/d Z d/d / dd
14 W W&^ K^ ^ Wmd dd D Z Z W l medl mddl & d E D Z Z Wld dded ^ K^ med med W l medl mddl D Z dd Z >d >&d K^ E & W&^ W l medl mddl D Z dd & d d ddd W&^ ^ d d ddl ' d d ddl del ' d d ddl del ' d d ddl K ^ d ^e d d eel ' d d ddl del dd
15 ' d d dl del ' d d dl del ' d d el D D Z d ee el d edl d eel d ddl d del & d md d dl le dl le dl le d d d dl le dl le d d E md d ee ddl d W mdl el lde dl le dl le K ee de ddl mddd d eel d K ^ d ^d e dld d d d dd
16 /D Z eel ldee /D / edl lee d d /D Z eel ldde /D / edl lee K ^ d ^e K d dl /D Z d dl /D / d d edl d d dddd d d d & d de ddl /D Z ddl ldd /D / ddl ldd dd ddl d d d dd dl d dl d dl K ^ d ^e d md dl d d dl dl d d dl dl d d dl dl d d dl dl d d dl d dl /D Z dl le /D / el le d d d d ded d dded d & d d d d d e d el /D Z el ldd /D / ddl le e del dd dl dd
17 d d K ^ d ^e / d dl /D Z dl ld /D / dl ld d d d D d dde de dddd K d d E d el /D Z ddl lde /D / el le dd del d d lde d le md d dl & d Z de ddl /D Z ddl lde /D / ddl ldd e del K ^ d ^e ^ dl d d dd d d ld d eed e deed Z d d d d d d d W de
18 K ^ d ^e K ed dd edl ldd ld ld le ld dd del d del d d E d / // WD> d D Z Z d edl eel d eel eel Z d d /D Z /D / de ddl d d d d de
19 D Z edl Z ddl d D Z del Z del, dd d t Z del del del d e dd W del W WD> dl d/d Z W d ^ dl d dd d K^ d d K^ edl edl d d edl eel edl WD> d</ e Z d dddd/ Dddds de Z >d d dd dd,z d del W Z D Z K dl dl ddd ddd D Z de
20 ' d eel del del / d edl ddl del dd d ddl d d d ' d d ddl ddl ddl del ddl ddl ddl ddl d d de Z ' d</ / WD> de de / d, edl d d d dd de dd de
21 e de D K^ W&^ W l mddl med d D Z Z > D Z dd K^ W&^, Z >d K^ >&d K^ d >&d >&d E /D W W d D> dd dd
22 d, : < d W / D : s ^ W, >> W / : E/ ddeeed ddeede dd
23 Z d ' W > D &y D : E / dddd ddd e ddd ded d s / ' E ^ > W Z ' W & ddd :, dddd ee dd ded dee d '>s & W / E W, E: ddde d d^/'e & W / E W, E: ddde d ^WZz> & W / D ^ W E: ddde e K^h>/& & W / W > E z Ez ddde e Z W W :& d K ddde dd d ddd ddd e : <, ddde :, ddde ed d ddd ded e : <, : h > D > dddd dd e ddd ddd dd
24 dd : <,D d, ^ ^</ ede W dddd dde de ddee ddee dd ' W d, < t dd :, dddd ee e edd edd dd d, : <,: & :, ddde ded d ee ddd dd ^ EW < t <, W Z > ddd, dddd ed d ddd ddd dd ^ EW <, < t ^ D> W : K dddd dd dd edde dd Z ^ W Z Z Z de Z > : K ddde de d dee ded dd
25 de />h^/' & W / Z/W / D ddde de : : <, <, > W :, ddde ed e ede ede de d, : ^ dd > :, dddd dee d ee ed de : ' W < t d Z & W t W W > > D > ddde de dd eed eed dd D D^ E / K dddd dd e dded ddee dd Z ^ D > Z Z d Z > :, dddd ee dd ddd dde dd D ^ ' ' : > E ddde dde e dede dedd dd
26 d d d ^ W /D Z lded /D / lee d lded D de e d e ee d de e d e ed d dd e d e ee d D de e d d ee d dd d d d ed d dd e d d ee d W md l ddd ee ee ed dde ed D e d eed dd d ded dd d eed D dd d eed dd d dde dd d eed W md l ee de dd de ddd dd D de e ddee dd e deed de e ddee Z ddd de e dedd dd dd deed dd e deed Z ddd ded de ddee dde de ddee ded de ddee D dde d deed ded d ddee dde d deed Z ddd dde d deee ed d ddee dee d deee Z ddd ddd d dedd dee d dded dde d dedd l ded ddd ee ddd ded ddd ed dd dd dd ed de dd de dd de ee dd W dd dd e e dd de W dd e dd dd dd e h de dd d d dd e d d d d e d / e d d d e d > d d d d d ^ d d d d d dd
27 W /D Z lded /D / lee d lded d d d d md K e d d d dd d l /D /l /D Zl Wl / W d d W K dd d K de de
28 d d K d dz /D Z lded /D / lee d lded W z d z d z d z d z d z d Z E l edl/ D Z ddd ded de de d@ed d dde ded de dd d@ee d de ed ed de e@ed e de ed ed de e@ed e ddd ded de dd d@ed e dde ded ed dd d@ed d Z ee ded dd de d@dd e ee ded de dd e@dd e dd ed dd de e@ed e dd ed dd dd d@ed e ddd ded de de e@dd d ddd ded dd dd d@dd e DDZ dd dde dd dd d@dd d de dde dd de d@dd d dd ed de de d@dd e dd ed de dd e@de d ed dee dd dd d@de d ed dee dd dd e@de e W D Z l edl/ ed d ed d ee e ee d de e ed e ee d ed d ed e ee e ed d ee d ee d ee d ed d ed d ed e ee d W Z l edl/ ee d ee e ed e ee e de e ee e ee e ed d ee e ee d de d ed d ee e ee d ed d ee d de e ee d W DDZ l edl/ ed e de d ed d ed e de d ed d ee d ed d ed e ed d de d ed e ed d de d ee d ee d de d ee d l edl/ de d dd d dd d dd d de e de e e e d d dd e dd d d d de e dd d dd d de e de d dd d dd d W WD> l edl/ d e d d dd d e d d e dd e d d d e e e d d d e e e d e d e e e d e d d e d K^ l edl/ ee d ed e ed d ed e ed e ee d ee e ed d ee d ee e ee d ed d ed d ee d ed d ed d ee d ee e de
29 Wl Wl Zl /l D>l /D /l /D Zl D Zl l DDZl K^l Wl d D Z Z d DDZ md Z >d Z W / Z ^ d DDZ d md < D Z D Z Z D> md mddldd e > md D Z W K^ d de
30 & > & d Z D Z Z Z Zl /D /l /D Zl D Zl K & d W Z > W K^l /Dl >&dl W llw W d dd, md W W K ^ D K & d < D K ^ /D /l /D Zl K K W d & d / E K K d l >dl ^dl hzd/l hd/l de
31 E d lded dd /,>'d W, ^K Wd ^ ^ ' ^K Wd Yd W Yd > Yd Yd d s / ^K /,>'d,>d E E E W E Wd &, d s E s E /,>'d s,>ds E Wd / / / / /,>dz Wd dd
32 ' ' dd
33
34
35
36
37 Supplementary Materials Methods Eligibility criteria Eligible patients were aged 18 years with a confirmed diagnosis of Philadelphia chromosome positive (Ph+) chronic phase (CP) chronic myeloid leukemia that was either resistant to full-dose imatinib or intolerant to any dose of imatinib. Primary imatinib resistance was defined as failure to achieve or maintain either hematologic improvement within 4 weeks, a complete hematologic response after 12 weeks, any cytogenetic response by 24 weeks, or a major cytogenetic response (MCyR) by 12 months with imatinib 600 mg/day. Acquired resistance was defined as loss of MCyR or hematologic response. Imatinib intolerance was defined as an inability to receive imatinib because of imatinib-related grade 4 hematologic adverse events (AEs) lasting >7 days, imatinib-related grade 3 nonhematologic AEs, grade 2 AEs that persist despite dose reductions and concomitant medications, or loss of response on lower-dose imatinib among patients with previous toxicity. In addition to prior imatinib therapy, patients were required to have an Eastern Cooperative Oncology Group Performance Status of 0 or 1, no antiproliferative or antileukemia treatment (with the exception of hydroxyurea or anagrelide) within 7 days of initiating bosutinib therapy, and adequate bone marrow function (imatinib-resistant patients), hepatic function, and renal function. Patients were excluded if they had a history of clinically significant or uncontrolled cardiac disease, had prolonged QTc 1
38 (average of >0.45 sec at screening), or had uncorrected hypomagnesemia or hypokalemia. Full eligibility criteria have been previously described. 10 Patients with documented history of T315I mutation could enroll in the study until a protocol amendment (May 28, 2008) made these patients ineligible. Patients already being treated could remain on study if enrollment had occurred before the amendment or if a baseline sample had subsequently tested positive for the T315I mutation. Statistical methods Time-to-event distributions and probabilities were estimated using the Kaplan- Meier method or cumulative incidence adjusting for the competing risk of treatment discontinuation without an event of PD/death or transformation. Two-sided 95% confidence intervals (CIs) for response rates and Kaplan-Meier quartiles were determined using the exact binomial and Brookmeyer-Crowley linear transformation methods, respectively. For Kaplan-Meier and cumulative incidence yearly probability estimates, two-sided 95% CIs were based on Greenwood s formula and Gray s method, respectively. Baseline and on-treatment (time-dependent) patient characteristics were evaluated as potential prognostic factors using backward-elimination, multivariate, cause-specific Cox regression models for duration of response and progression-free survival and a multivariate Cox regression model for overall survival. P values <0.05 were statistically significant and no adjustments for multiple comparisons were made. 2
39 Backward elimination criteria was 0.20 for all models. Results are presented as hazard ratios (95% confidence intervals). Covariates for multivariate Cox regression analysis Prior response to imatinib was defined as achievement of at least a minimal cytogenetic response (standard cytogenetic criteria: 66% 95% Ph+ cells from bone marrow or BCR-ABL1 from fluorescence in situ hybridization [FISH]). Determination of Ph+ ratio occurred during the screening visit within 14 days before registration of the patient in the study and required 20 metaphases for standard cytogenetics or 200 cells for FISH. Disease duration is defined as the time between the primary diagnosis and date of administration of first dose of study drug. Patients initiating imatinib treatment 6 months after diagnosis or after prior interferon therapy were considered to be in late CP. Bosutinib-sensitive mutations are those resulting in half maximal inhibitory concentration (IC 50 ) 3-fold higher than wild type (M244V, Q252H, Y253H, Y253F, D276G, E279K, E292L, F317L, M343T, M351T, F359I, F359V, L384M, H396P, H396R, G398R, F486S); moderately bosutinib-resistant mutations are those with IC 50 values 3 to 10-fold higher than wild type (L248V, G250E, E255V, and T315A); highly bosutinib-resistant mutations are those with IC 50 values >10-fold higher than wild type (L248R, L248R+F359I, E255K, V299L, T315I, T315V, F317R, F317V); the sensitivity of all other mutations is unknown. 15,21 Patients with multiple mutations of different sensitivities were categorized based on the following hierarchy: highly bosutinibinsensitive, bosutinib-insensitive, unknown sensitivity, and bosutinib-sensitive. 3
40 Supplementary Table S1. Demographics and Baseline Disease Characteristics IM-R (n=195) IM-I (n=89) Total (n=284) Median (range) age, y 51 (18 86) 55 (23 91) 53 (18 91) <65 y, n (%) 159 (82) 62 (70) 221 (78) 65 y, n (%) 36 (18) 27 (30) 63 (22) Men, n (%) 113 (58) 36 (40) 149 (52) Race, n (%) White Asian Black Other ECOG Performance Status, n (%) (67) 41 (21) 11 (6) 12 (6) 151 (77) 44 (23) 0 55 (62) 21 (24) 5 (6) 8 (9) 66 (74) 21 (24) 1 (1) 186 (65) 62 (22) 16 (6) 20 (7) 217 (76) 65 (23) 1 (<1) Median time since CML diagnosis (range), y 4.1 ( ) 2.7 ( ) 3.7 ( ) Number of prior therapies, n (%) (61) 66 (74) 184 (65) 2 77 (39) 23 (26) 100 (35) Prior non-tki therapies, n (%) Interferon Stem cell transplant 77 (39) 23 (26) 6 (3) 2 (2) CML=chronic myeloid leukemia; ECOG=Eastern Cooperative Oncology Group; IM-I=imatinib intolerant; IM-R=imatinib-resistant; TKI=tyrosine kinase inhibitor. 100 (35) 8 (3) 4
41 Supplementary Table S2. Treatment Discontinuations by Year of Treatment* Reasons for Discontinuation Year 1 (n=284) Year 2 (n=197) Year 3 (n=153) Year 4 (n=136) Year 5 (n=123) Total (n=284) Discontinued treatment, n (%) 87 (31) 44 (22) 17 (11) 13 (10) 8 (7) 284 (100) AE 47 (17) 10 (5) 2 (1) 4 (3) 1 (1) 67 (24) PD 21 (7) 15 (8) 7 (5) 3 (2) 1 (1) 51 (18) Patient request 9 (3) 5 (3) 2 (1) 2 (1) 1 (1) 24 (8) Unsatisfactory response (efficacy) 5 (2) 9 (5) 4 (3) 1 (1) 2 (2) 23 (8) Death 0 2 (1) 1 (1) 0 2 (2) 8 (3) Investigator request 1 (<1) 0 1 (1) 1 (1) 0 8 (3) Lost to follow-up 1 (<1) 1 (<1) 0 2 (1) 0 4 (1) Symptomatic deterioration 1 (<1) 1 (<1) (1) Other 2 (1) 1 (<1) (1) 96 # (34) Discontinuation due to any AE,,ǁ n Thrombocytopenia Neutropenia ALT increased Diarrhea Rash AST increased Anemia Pneumonia Intestinal obstruction Abdominal adhesions Cardiac failure Lipase increased White blood cell count increased CAD Scleroderma Renal failure
42 Ascites Serositis Increased blood creatinine Pulmonary hypertension AE=adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CAD=coronary artery disease; PD=progressive disease. *In both Parts 1 and 2, patients received treatment until PD, death, unacceptable toxicity, or withdrawal of consent; denominators for years 1 5 are the number of patients on treatment during those time periods. Includes data after year 5 until the cutoff date. One year=48 weeks. AEs presented include those resulting in treatment discontinuation in years 2 5 or in 1% of patients overall. ǁ Totals are not necessarily the sum of those for individual AEs as patients may report multiple AEs leading to discontinuation. The same patient discontinued due to ascites and serositis. # Includes patients who enrolled in an extension study and those for whom discontinuation of study by the sponsor was the primary reason for treatment discontinuation. 6
43 Supplementary Table S3. Treatment Outcomes for Patients Aged 65 and 65 Years 65 y Parameter (n=221) Response,* n/n evaluable (%) [95% CI] Attained/maintained MCyR 123/201 (61) [ ] Attained MCyR 115/192 (60) [ ] Attained/maintained CCyR 101/201 (50) [ ] Attained CCyR 93/192 (48) 65 y (n=63) Total (n=284) 33/61 (54) [ ] 156/262 (60) [ ] 26/54 (48) 141/246 (57) [ ] [ ] 29/61 (48) 130/262 (50) [ ] [ ] 23/54 (43) 116/246 (47) [ ] [ ] [ ] Probability of maintaining MCyR at 5 y, % [95% CI] 73 [64 81] 63 [42 78] 71 [63 78] Probability of maintaining CCyR at 5 y, % [95% CI] 73 [62 81] 58 [35 75] 69 [60 77] 1 dose interruption due to AEs, n (%) 159 (72) 50 (79) 209 (74) 1 dose reduction due to AEs, n (%) 105 (48) 36 (57) 141 (50) On-treatment death due to an AE, n (%) 3 (1) 2 (3) 5 (2) Discontinued treatment, n (%) 221 (100) 63 (100) 284 (100) Enrolled in extension study 71 (32) 12 (19) 83 (29) AE 47 (21) 20 (32) 67 (24) PD 41 (19) 10 (16) 51 (18) Patient request 15 (7) 9 (14) 24 (8) Efficacy 18 (8) 5 (8) 23 (8) Other 12 (5) 1 (2) 13 (5) Death 3 (1) 5 (8) 8 (3) Investigator request 7 (3) 1 (2) 8 (3) Lost to follow-up 4 (2) 0 4 (1) Symptomatic deterioration 2 (1) 0 2 (1) 7
44 Study discontinued by sponsor 1 (<1) 0 1 (<1) Transformation to AP/BP CML at 5 y, ǁ % [95% CI] 5 [3 9] 3 [1 12] 5 [3 8] PD/death at 5 y, % [95% CI] 19 [15 25] 19 [11 32] 19 [15 24] OS at 5 y,,** % [95% CI] 85 [79 90] 77 [61 86] 84 [78 88] AE=adverse event; AP=accelerated phase; BP=blast phase; CCyR=complete cytogenetic response; CI=confidence interval; CML=chronic myeloid leukemia; MCyR=major cytogenetic response; OS=overall survival; PD=progressive disease. *Response among evaluable patients. Response could be newly achieved during the study or maintained from baseline for 4 weeks and was determined using standard cytogenetics with 20 metaphases counted for postbaseline assessments (fluorescence in situ hybridization analysis of bone marrow aspirate or peripheral blood with 200 cells to detect BCR- ABL1 was used if 20 metaphases were available postbaseline). 22 Evaluable patients received 1 bosutinib dose and had a valid baseline assessment of cytogenetic response with 20 metaphases or 1 Ph+ metaphase from bone marrow cytogenetics. Patients with a CCyR at baseline were excluded from the attained-only analyses. Based on Kaplan-Meier estimates. AEs resulting in death were acute cardiac decompensation, heart failure and chronic obstructive pulmonary disease (same patient), congestive heart failure, suicide, and pneumonia. ǁ Based on cumulative incidence adjusting for competing risk of treatment discontinuation without transformation. Based on cumulative incidence adjusting for competing risk of treatment discontinuation without PD or death; PD defined as transformation to AP or BP CML, increasing white blood cell count (doubling over 1 mo with second count > /L and confirmed 1 week later), or loss of confirmed complete hematologic response or unconfirmed MCyR). ** Analysis includes data from the long-term extension study. 8
45 Supplementary Table S4. Cytogenetic Response Before and After Bosutinib Dose Reduction IM-R (n=195) IM-I (n=89) Total (n=284) Patients reducing dose to 400 mg, n Attained/maintained MCyR,* n (%) 51 (63) 30 (59) 81 (61) MCyR after reduction 39 (48) 18 (35) 57 (43) Median (range) duration of MCyR (non-k-m), wk 134 (0 338) 185 (0 290) 167 (0 338) MCyR before and after reduction 9 (11) 10 (20) 19 (14) Median (range) duration of MCyR (non-k-m), wk 299 (11 324) 281 (44 342) 283 (11 342) MCyR before but not after reduction 3 (4) 2 (4) 5 (4) Newly-attained MCyR,* n (%) 44 (63) 23 (58) 67 (61) Attained MCyR after reduction 32 (46) 16 (40) 48 (44) Median (range) duration of MCyR (non-k-m), wk 122 (0 338) 185 (0 290) 150 (0 338) Attained MCyR before and after reduction 9 (13) 6 (15) 15 (14) Median (range) duration of MCyR (non-k-m), wk 299 (11 324) 281 (44 342) 283 (11 342) Attained MCyR before but not after reduction 3 (4) 1 (3) 4 (4) Patients reducing dose to 300 mg, n Attained/maintained MCyR, n (%) 22 (69) 7 (39) 29 (58) MCyR after reduction 6 (19) 2 (11) 8 (16) Median (range) duration of MCyR (non-k-m), wk 17 (0 251) 116 (0 233) 17 (0 251) MCyR before and after reduction 15 (47) 5 (28) 20 (40) Median (range) duration of MCyR (non-k-m), wk 252 (11 323) 276 (97 331) 260 (11 331) MCyR before but not after reduction 1 (3) 0 1 (2) Newly-attained MCyR, n (%) 20 (69) 5 (36) 25 (58) 9
46 Attained MCyR after reduction 7 (24) 2 (14) 9 (21) Median (range) duration of MCyR (non-k-m), wk 22 (0 251) 116 (0 233) 22 (0 251) Attained MCyR before and after reduction 12 (41) 3 (21) 15 (35) Median (range) duration of MCyR (non-k-m), wk 254 (11 323) 276 (97 283) 267 (11 323) Attained MCyR before but not after reduction 1 (3) 0 1 (2) IM-I=imatinib intolerant; IM-R=imatinib-resistant; K-M=Kaplan-Meier; MCyR=major cytogenetic response. *Denominators are the number of patients who dose reduced to bosutinib 400 mg daily for the respective cohort. Denominators for newly-attained response rates also exclude patients with CCyR at baseline. Denominators are the number of patients who dose reduced to bosutinib 300 mg daily for the respective cohort. Denominators for newly-attained response rates also exclude patients with CCyR at baseline. 10
47 Supplementary Table S5. Incidence of and Response by Mutation Status Incidence* Response to BOS, n/n Evaluable IM-R IM-I Total CHR MCyR Baseline Patients assessed for mutations at baseline, n / /208 No mutation at baseline 83 (53) 62 (91) 145 (65) 128/145 75/130 1 mutation 60 (38) 6 (9) 66 (29) 56/65 40/66 1 mutations 73 (47) 6 (9) 79 (35) 66/78 46/78 2 mutations 13 (8) 0 13 (6) 10/13 6/12 Individual mutations L248V 5 (3) 0 5 (2) 5/5 3/5 G250E 6 (4) 0 6 (3) 5/6 3/5 Y253F 1 (1) 0 1 (<1) 1/1 0 Y253H 4 (3) 0 4 (2) 4/4 4/4 E255K 3 (2) 0 3 (1) 0 2/3 E255V 2 (1) 0 2 (1) 2/2 1/2 M244V 6 (4) 0 6 (3) 6/6 4/6 D276G 1 (1) 0 1 (<1) 1/1 0 E286G 1 (1) 0 1 (<1) 1/1 1/1 L298V 1 (1) 0 1 (<1) 0 0 F311I 2 (1) 0 2 (1) 2/2 1/2 F311L 2 (1) 0 2 (1) 2/2 2/2 T315I 9 (6) 0 9 (4) 2/9 2/9 F317L 4 (3) 0 4 (2) 4/4 3/4 N331S 1 (1) 0 1 (<1) 1/1 1/1 V338A 1 (1) 0 1 (<1) 1/1 1/1 11
48 M351T 8 (5) 0 8 (4) 8/8 7/8 E355A 1 (1) 0 1 (<1) 1/1 1/1 E355G 1 (1) 0 1 (<1) 1/1 1/1 F359I 1 (1) 0 1 (<1) 1/1 1/1 F359S 0 1 (1) 1 (<1) 1/1 1/1 F359V 8 (5) 1 (1) 9 (4) 8/9 4/9 L364P 1 (1) 0 1 (<1) 1/1 1/1 N368S 1 (1) 0 1 (<1) 1/1 0 L387F 0 1 (1) 1 (<1) 1/1 0 L387M 1 (1) 0 1 (<1) 1/1 1/1 M388L 1 (1) 0 1 (<1) 1/1 1/1 H396P 1 (1) 1 (1) 2 (1) 2/2 2/2 H396R 2 (1) 0 2 (1) 1/2 0 T406A 1 (1) 0 1 (<1) 1/1 0 S417F 1 (1) 0 1 (<1) 1/1 1/1 D421G 1 (1) 0 1 (<1) 1/1 0 I432T 1 (1) 0 1 (<1) 1/1 0 E450G 1 (1) 0 1 (<1) 1/1 0 E450V 1 (1) 0 1 (<1) 1/1 1/1 E453G 1 (1) 0 1 (<1) 0 0 E453K 0 1 (1) 1 (<1) 1/1 1/1 E453Q 1 (1) 0 1 (<1) 1/1 1/1 E453R 1 (1) 0 1 (<1) 0 0 E459K 0 1 (1) 1 (<1) 1/1 0 K459G 1 (1) 0 1 (<1) 1/1 0 K459R 1 (1) 0 1 (<1) 1/1 0 P480A 1 (1) 0 1 (<1) 1/1 1/1 12
49 Best Response to BOS, n/n With Mutation CHR PCyR CCyR Newly-emerging Patients assessed for new mutations, n Patients with new mutations 20 (27) 6 (19) 26 (25) Individual mutations T315I,, 7 (35) 2 (33) 9 (35) 5/9 2/9 1/9 V299L 3 (15) 2 (33) 5 (19) 3/5 1/5 1/5 M244V 1 (5) 1 (17) 2 (8) 0 0 1/2 E255V 1 (5) 0 1 (4) 1/1 0 0 E450A 1 (5) 0 1 (4) 1/1 0 0 E450G 0 1 (17) 1 (4) 1/1 0 0 F359V 1 (5) 0 1 (4) 0 0 1/1 G250E, 1 (5) 0 1 (4) 1/1 0 0 H295L 1 (5) 0 1 (4) 0 0 1/1 K378E 1 (5) 0 1 (4) 0 1/1 0 L273M 1 (5) 0 1 (4) 0 0 1/1 S348L 1 (5) 0 1 (4) 0 0 1/1 S410G 1 (5) 0 1 (4) 0 0 1/1 BOS=bosutinib; CHR=complete hematologic response; CCyR=complete cytogenetic response; IM-I=imatinib-intolerant; IM-R=imatinib-resistant; MCyR=major cytogenetic response; PCyR=partial cytogenetic response. Values are expressed as n (%) unless otherwise noted. Shaded rows indicate mutations that are resistant (light gray) or highly resistant (dark gray) to BOS. 15 *Denominators are number of patients assessed for mutations at baseline or newly-emerging during the study. Newly-emerging mutations are those not present at baseline. Mutations that are resistant or highly resistant to dasatinib. Mutations that are resistant or highly resistant to nilotinib. One patient had no detectable response. 13
50 Supplementary Table S6. TEAEs Occurring in 10% of Patients and Laboratory Abnormalities Occurring in 30% of Patients Overall IM-R (n=195) IM-I (n=89) Total (n=284) TEAE, n (%) All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4 Any TEAE 194 (99.5) 145 (74.4) 89 (100) 75 (84.3) 283 (99.6) 220 (77.5) Hematologic* Thrombocytopenia 77 (39.5) 45 (23.1) 41 (46.1) 27 (30.3) 118 (41.5) 72 (25.4) Anemia 51 (26.2) 23 (11.8) 32 (36.0) 15 (16.9) 83 (29.2) 38 (13.4) Neutropenia 29 (14.9) 16 (8.2) 17 (19.1) 12 (13.5) 46 (16.2) 28 (9.9) Leukopenia 22 (11.3) 8 (4.1) 15 (16.9) 7 (7.9) 37 (13.0) 15 (5.3) Gastrointestinal Diarrhea 167 (85.6) 18 (9.2) 76 (85.4) 9 (10.1) 243 (85.6) 27 (9.5) Nausea 85 (43.6) 1 (0.5) 46 (51.7) 4 (4.5) 131 (46.1) 5 (1.8) Vomiting 73 (37.4) 3 (1.5) 33 (37.1) 8 (9.0) 106 (37.3) 11 (3.9) Abdominal pain 52 (26.7) 4 (2.1) 25 (28.1) 2 (2.2) 77 (27.1) 6 (2.1) Upper abdominal pain 42 (21.5) 1 (0.5) 17 (19.1) 0 59 (20.8) 1 (0.4) Constipation 22 (11.3) 0 17 (19.1) 1 (1.1) 39 (13.7) 1 (0.4) Infections and infestations Nasopharyngitis 25 (12.8) 0 13 (14.6) 0 38 (13.4) 0 Urinary tract infection 22 (11.3) 2 (1.0) 8 (9.0) 0 30 (10.6) 2 (0.7) Influenza 22 (11.3) 0 7 (7.9) 2 (2.2) 29 (10.2) 2 (0.7) Upper respiratory tract infection 19 (9.7) 0 10 (11.2) 1 (1.1) 29 (10.2) 1 (0.4) Investigations ALT increased 42 (21.5) 15 (7.7) 21 (23.6) 9 (10.1) 63 (22.2) 24 (8.5) AST increased 38 (19.5) 7 (3.6) 18 (20.2) 4 (4.5) 56 (19.7) 11 (3.9) Weight decreased 28 (14.4) 1 (0.5) 8 (9.0) 2 (2.2) 36 (12.7) 3 (1.1) Other Rash 64 (32.8) 15 (7.7) 39 (43.8) 11 (12.4) 103 (36.3) 26 (9.2) Pyrexia 58 (29.7) 1 (0.5) 18 (20.2) 2 (2.2) 76 (26.8) 3 (1.1) 14
51 Fatigue 49 (25.1) 1 (0.5) 24 (27.0) 2 (2.2) 73 (25.7) 3 (1.1) Cough 46 (23.6) 0 19 (21.3) 0 65 (22.9) 0 Headache 35 (17.9) 0 18 (20.2) 0 53 (18.7) 0 Arthralgia 31 (15.9) 2 (1.0) 17 (19.1) 1 (1.1) 48 (16.9) 3 (1.1) Decreased appetite 30 (15.4) 2 (1.) 12 (13.5) 0 42 (14.8) 2 (0.7) Asthenia 26 (13.3) 7 (3.6) 16 (18.0) 0 42 (14.8) 7 (2.5) Back pain 22 (11.3) 1 (0.5) 16 (18.0) 0 38 (13.4) 1 (0.4) Oropharyngeal pain 25 (12.8) 0 10 (11.2) 0 35 (12.3) 0 Dyspnea 24 (12.3) 5 (2.6) 10 (11.2) 0 34 (12.0) 5 (1.8) Pain in extremity 28 (14.4) 2 (1.0) 4 (4.5) 0 32 (11.3) 2 (0.7) Pleural effusion 21 (10.8) 5 (2.6) 9 (10.1) 4 (4.5) 30 (10.6) 9 (3.2) Cardiac AEs 25 (12.8) 11 (5.6) 12 (13.5) 5 (5.6) 37 (13.0) 16 (5.6) Vascular AEs 13 (6.7) 9 (4.6) 9 (10.1) 2 (2.2) 22 (7.7) 11 (3.9) Hypertension-related AEs ǁ 19 (9.7) 7 (3.6) 7 (7.9) 1 (1.1) 26 (9.2) 8 (2.8) Renal AEs 27 (13.8) # 5 (2.6) 10 (11.2) 1 (1.1) 37 (13.0) # 6 (2.1) Laboratory Abnormalities, n (%) All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4 Any laboratory abnormality 194 (99.5) 136 (69.7) 89 (100) 68 (76.4) 283 (99.6) 204 (71.8) Hematologic Low hemoglobin 180 (92.3) 24 (12.3) 76 (85.4) 17 (19.1) 256 (90.1) 41 (14.4) Low lymphocytes 149 (76.4) 25 (12.8) 71 (79.8) 16 (18.0) 220 (77.5) 41 (14.4) Low platelet count 131 (67.2) 47 (24.1) 64 (71.9) 27 (30.3) 195 (68.7) 74 (26.1) Low WBC count 102 (52.3) 13 (6.7) 47 (52.8) 10 (11.2) 149 (52.5) 23 (8.1) Low ANC 98 (50.3) 25 (12.8) 47 (52.8) 19 (21.3) 145 (51.1) 44 (15.5) Nonhematologic High ALT 109 (55.9) 20 (10.3) 61 (68.5) 13 (14.6) 170 (59.9) 33 (11.6) High AST 97 (49.7) 8 (4.1) 50 (56.2) 7 (7.9) 147 (51.8) 15 (5.3) Low phosphorous 91 (46.7) 20 (10.3) 35 (39.3) 6 (6.7) 126 (44.4) 26 (9.2) Low calcium 85 (43.6) 6 (3.1) 40 (44.9) 4 (4.5) 125 (44.0) 10 (3.5) 15
52 High glucose 87 (44.6) 4 (2.1) 29 (32.6) 5 (5.6) 116 (40.8) 9 (3.2) High creatinine 78 (40.0) 5 (2.6) 38 (42.7) 2 (2.2) 116 (40.8) 7 (2.5) High alkaline phosphatase 73 (37.4) 0 34 (38.2) (37.7) 0 Low bicarbonate 62 (31.8) 0 28 (31.5) 1 (1.1) 90 (31.7) 1 (0.4) High lipase 57 (29.2) 24 (12.3) 32 (36.0) 9 (10.1) 89 (31.3) 33 (11.6) AE=adverse event; ALT=alanine aminotransferase; ANC=absolute neutrophil count; AST=aspartate aminotransferase; IM-I=imatinibintolerant; IM-R=imatinib-resistant; TEAE=treatment-emergent adverse event; WBC=white blood cell. *Hematologic TEAEs (thrombocytopenia, anemia, neutropenia, leukopenia) were clustered separately with the corresponding terms from the Medical Dictionary for Regulatory Activities system order class (SOC) Investigations (Platelet count decreased, Hemoglobin decreased, Neutrophil count decreased, WBC count decreased). Includes the high-level group terms (HLGTs) Cardiac arrhythmias, Pericardial disorders, and Heart failures under the Cardiac disorders SOC; the preferred terms (PTs) Cardiac death, Sudden cardiac death, and Sudden death under the General disorders and administration site conditions SOC; the PTs Decreased ejection fraction, Abnormal electrocardiogram QT interval, Prolonged electrocardiogram QT, Torsade de pointes, Ventricular tachycardia, Congenital long QT syndrome under the Investigations SOC. Includes 2 patients who had grade 5 events. Includes the HLGTs Coronary artery disorders, Arteriosclerosis, stenosis, vascular insufficiency and necrosis, and Embolism and thrombosis; the high-level terms (HLTs) Arterial therapeutic procedures (excluding aortic), Central nervous system hemorrhages and cerebrovascular accidents, and Central nervous system vascular disorders not elsewhere classified (NEC); Non-site specific vascular disorders NEC, Peripheral vascular disorders NEC (excluding the PTs Flushing and Hot flash), Transient cerebrovascular events, Vascular imaging procedures NEC, and Vascular therapeutic procedures NEC. ǁ Includes HLGTs Vascular hypertensive disorders and Cardiac and vascular investigations (excluding enzyme tests), the HLT Vascular tests NEC (including blood pressure) and the PTs Abnormal blood pressure, Abnormal ambulatory blood pressure, Increased ambulatory blood pressure, Abnormal diastolic blood pressure, Increased diastolic blood pressure, Increased blood pressure, Abnormal systolic blood pressure, and Increased systolic blood pressure. Includes the HLT Renal failure and impairment; the PTs Blood creatinine abnormal, Blood creatinine increased, Creatinine renal clearance abnormal, Creatinine renal clearance decreased, Glomerular filtration rate abnormal, and Glomerular filtration rate decreased. # Includes 1 patient who had a grade 5 event. 16
53 Supplementary Table S7. Cross-Intolerance* in Patients Intolerant to Imatinib Outcome with BOS Due to Same AE Reason for Prior Intolerance Intolerant to Prior IM, n Same AE on BOS, n (%) Dose Delay, n (%) Dose Reduction, n (%) Discontinued, n (%) Any AE (61) 25 (29) 14 (16) 14 (16) Hematologic disorders Anemia 11 5 (45) 1 (9) 0 0 Leukopenia 4 1 (25) 1 (25) 0 0 Neutropenia 13 5 (38) 3 (23) 2 (15) 2 (15) Thrombocytopenia (75) 8 (50) 6 (38) 4 (25) Gastrointestinal disorders Diarrhea 7 6 (86) 2 (29) 2 (29) 1 (14) Nausea 5 4 (80) 1 (20) 0 0 Vomiting 4 2 (50) 2 (50) 0 1 (25) Other Fatigue 6 2 (33) 1 (17) 1 (17) 1 (17) Edema 10 4 (40) Liver disorder 3 1 (33) Fluid retention Myalgia 4 1 (25) 0 1 (25) 0 Rash 12 8 (67) 4 (33) 0 1 (8) AE=adverse event; BOS=bosutinib; IM=imatinib. *Defined as discontinuing bosutinib and a prior tyrosine kinase inhibitor due to the same AE. Defined as permanent discontinuation due to this treatment-emergent AE; AEs leading to discontinuation in 3 prior imatinib-treated patients are presented. The specific AE reported as the reason for discontinuation of prior imatinib was unknown for 4 patients. 17
54 Figure S1. Patient Disposition. Enrollment (N=284) IM-R (n=195) IM-I (n=89) Discontinued (n=135) Enrolled in extension study n=61 Death n=37 Lost to follow-up n=12 Patient request n=9 Study discontinued by sponsor n=1 Other n=15 Discontinued (n=50) Enrolled in extension study n=27 Death n=7 Lost to follow-up n=4 Patient request n=8 Study discontinued by sponsor n=0 Other n=4 Completed study (n=60) Completed study (n=39) Evaluable Patients Safety* n=195 Molecular response n=127 Cytogenetic response n=182 Hematologic response n=194 Evaluable Patients Safety* n=89 Molecular response n=70 Cytogenetic response n=80 Hematologic response n=89 IM-I=imatinib-intolerant; IM-R=imatinib-resistant. *Includes all patients who received 1 dose. Not assessed using the international scale; data from patients at sites in China, India, Russia, and South Africa are not available. 18
Published Ahead of Print on July 9, 2015, as doi: /haematol Copyright 2015 Ferrata Storti Foundation.
Published Ahead of Print on July 9, 2015, as doi:10.3324/haematol.2015.125864. Copyright 2015 Ferrata Storti Foundation. Impact of prior treatment and depth of response on survival in MM-003, a randomized
More informationMediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the LYSA
Published Ahead of Print on October 6, 2016, as doi:10.3324/haematol.2016.152256. Copyright 2016 Ferrata Storti Foundation. Mediastinal Grey Zone Lymphoma: clinico-pathological characteristics and outcomes
More informationPublished Ahead of Print on August 16, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on August 16, 2018, as doi:10.3324/haematol.2018.196121. Copyright 2018 Ferrata Storti Foundation. Computed tomography pulmonary angiography versus ventilation-perfusion lung scan
More informationPublished Ahead of Print on May 10, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on May 10, 2018, as doi:10.3324/haematol.2017.186569. Copyright 2018 Ferrata Storti Foundation. Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years)
More informationR-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)
R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL) Thierry Lamy, Gandhi Damaj, Pierre Soubeyran, Emmanuel Gyan, Guillaume Cartron, Krimo Bouabdallah,
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Elter T, Gercheva-Kyuchukova L, Pylylpenko
More informationPublished Ahead of Print on August 1, 2014, as doi: /haematol Copyright 2014 Ferrata Storti Foundation.
Published Ahead of Print on August 1, 2014, as doi:10.3324/haematol.2014.106096. Copyright 2014 Ferrata Storti Foundation. Outcome of Aplastic Anemia in adolescence. A survey of the Severe Aplastic Anemia
More informationd ^dzd K DZ/ '^ ^ '^ K '^ / '^ / DZ/ W / ^ d Eled ^ d Eldd dd d e t d d e de ^ '^ de ddl '^
DZ/, ^ : ' t ' D ^ E > E / D, ^ : ' W > E/D, E/, dd Z d dde Dddeed ddee ddd ddd dede E /, D d ^dzd K DZ/ '^ ^ '^ K '^ / '^ / DZ/ W / ^ d Eled ^ d Eldd dd d e t d d e de ^ '^ de ddl '^ d d '^ t '^ d /EdZKhd/KE
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of
More informationPublished Ahead of Print on May 24, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on May 24, 2018, as doi:10.3324/haematol.2018.193151. Copyright 2018 Ferrata Storti Foundation. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia
More informationPublished Ahead of Print on September 29, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on September 29, 2017, as doi:10.3324/haematol.2017.174441. Copyright 2017 Ferrata Storti Foundation. Mixed phenotype acute leukemia: Outcomes with allogeneic stem cell transplantation,
More informationW W D D ddd ^ D,, Z > tdddee d lddddddededdedd ' d W d
dd WZde de& WZddd ' d d d E < d K d ' ^ d Z d Z E ' d d >, d K D d K d Z E d > E d D e E ^ e W D D d d ^ D / > > h < d W D / W W E < > > h < d / / ^ > h < d Y ^ D ^ / E h > > h < d / > > h < e D ^ E h
More informationSrdan Verstovsek, MD, PhD Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Efficacy and Safety of Pegylated Interferon Alpha- 2a in Patients with Essential Thrombocythemia (ET) and Polycythemia vera (PV): Results after a Median 7-year Follow-up of a Phase 2 Study Srdan Verstovsek,
More informationh D t del d ddl ddl el del d < d
> Z Z d : d h D d, Z d d / d W < ^ d d d ' e W E e > ^ d d / & d e ^ < e Z d e & D d e h s d : ^ d e d ' D ' h ' ' ' d / / ' h ^ ^ ' d / / ' & ' h D ' ' ' d W ' h ' ' ' d ' D ' ' > ' h ' ' ' e D /' /EZh
More informationCopyright 2010 by the American Society for Pharmacology and Experimental Therapeutics.
DMD This Fast article Forward. has not been Published copyedited and on formatted. July 15, The 2010 final as version doi:10.1124/dmd.110.033936 may differ from this version. / & W W, / > W > Z z d >,
More informationPhase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
Publishe Ahea of Print on February 20, 2015, as oi:10.3324/haematol.2014.119735. Copyright 2015 Ferrata Storti Founation. Phase I/II Stuy of the Combination of Panobinostat an Carfilzomib in Patients with
More informationPopulation pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
Published Ahead of Print on November 10, 2016, as doi:10.3324/haematol.2016.149195. Copyright 2016 Ferrata Storti Foundation. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric
More informationCASE REPORT FORM (April 2012)
CASE REPORT FORM (April 2012) Surveillance of Paediatric Dengue National Paediatric Hospital, Phnom Penh Kingdom of Cambodia Study contact: I am confident that the information supplied in this case record
More informationBlood First Edition Paper, prepublished online March 7, 2018; DOI /blood
Blood First Edition Paper, prepublished online March 7, 2018; DOI 10.1182/blood-2017-12-822817 ^ E& /s>> > >zdw,k/ekw>^/, Dzee ee D Z ^ d W D : d Z t d D, s d D : d ^ & ^ d :,, s d Z d t < d D : < d D
More informationOverview of the Accountancy Profession in China
2016I1-024 Overview of the Accountancy Profession in China (Released by CICPA, Updated on January 21, 2016) /K D d // / W d ///^ d d d /s^ / ^ e s^ W D & e s/^ E ^ e s///d^ W e s///y W dd /y/ dd y/ dd
More informationCan we reduce health inequalities? An analysis of the English strategy ( )
Can we reduce health inequalities? An analysis of the English strategy (1997-2010) Johan P Mackenbach To cite this version: Johan P Mackenbach. Can we reduce health inequalities? An analysis of the English
More informationDesmopressin in moderate hemophilia A patients: a treatment worth considering
Published Ahead of Print on January 5, 2018, as doi:10.3324/haematol.2017.180059. Copyright 2018 Ferrata Storti Foundation. Desmopressin in moderate hemophilia A patients: a treatment worth considering
More informationMolecular Pharmacology Fast Forward. Published on June 29, 2016 as DOI: /mol This article has not been copyedited and formatted.
, W D E / & h E D D D Z W, W D / & h dddd h D D d dddddedddede dddddeddddee & dddddedddede d d d & d dee d eddd Z dde DW d d d W/ d d e e d d d d d, d /^ d db d db E< E l
More informationMolecular Pharmacology Fast Forward. Published on January 6, 2017 as DOI: /mol This article has not been copyedited and formatted.
d/d>w' d zddd & Z d ' W d : z t Z ' :, & D W, > > d/w/ D^ Z / Dh^ d W zt Z' d D^ Z / Dh^ ' d: :, &D >> d/w/ D ^ ' W, d ZhEE/E'd/d>W' Z W D^ Z / ddd d Dddedd ld eee ded dddd d de E d E e E de ddd / edd
More informationhzkwekdd/^^/ke /ZdKZd 'EZ> >/Ddd/KE / D ' e h d^ dddd, & & dd dddd d
hzkwekdd/^^/ke /ZdKZd'EZ> >/D/KE /D 'e hd^,& & d d d / d dd ^' d dd /D' d dd h' d dd d dd ^ d de W d d, e dd,d^ e dd,d^d^ dd,d^d^ d, dd K dd,d^ de dd,d^ dd D dd D de d ^d: dd dd d ^ dd, dd, d d / dd ^'
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus
CHAPTER 3 Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus Expert Panel: Mr Mohamed Ezani Md. Taib (Chairperson) Dr Abdul Rais Sanusi Datuk Dr Aizai Azan Abdul Rahim Dr Ashari
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus
CHAPTER 3 HEART AND LUNG TRANSPLANTATION Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus Expert Panel: Mr Mohamed Ezani Md. Taib (Chairperson) Dr Abdul Rais Sanusi Datuk
More informationPhase 3 results for vosaroxin/cytarabine in the subset of patients 60 years old with refractory/early relapsed acute myeloid leukemia
Publishe Ahea of Print on May 24, 2018, as oi:10.3324/haematol.2018.191361. Copyright 2018 Ferrata Storti Founation. Phase 3 results for vosaroxin/cytarabine in the subset of patients 60 years ol with
More informationHistorical review of glasses used for parenteral packaging
Downloaded from on November 13, 2018 Historical review of glasses used for parenteral packaging Robert A Schaut and W. Porter Weeks PDA Journal of Pharmaceutical Science and Technology 2017, Access the
More informationTreatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the EXELS study
Published Ahead of Print on October 27, 2017, as doi:10.3324/haematol.2017.174672. Copyright 2017 Ferrata Storti Foundation. Treatment of essential thrombocythemia in Europe: a prospective long-term observational
More informationThe OPTIM program and TKI therapeutic drug monitoring
The OPTIM program and TKI therapeutic drug monitoring Philippe Rousselot Université de Versailles Saint-Quentin-en-Yvelines Université Paris-Saclay Hôpital André Mignot, Hôpitaux de Versailles, France
More informationNCCTG Status Report for Study N May 2010
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Purpose of - Objectives Study: 1) Study 1: To identify the MTD of imatinib
More informationDynamic Prediction of Disease Progression Using Longitudinal Biomarker Data
Dynamic Prediction of Disease Progression Using Longitudinal Biomarker Data Xuelin Huang Department of Biostatistics M. D. Anderson Cancer Center The University of Texas Joint Work with Jing Ning, Sangbum
More informationHIF-1 can act as a tumor suppressor gene in murine Acute Myeloid Leukemia.
HIF-1 can act as a tumor suppressor gene in murine Acute Myeloid Leukemia. Velasco, Talia; Hyrenius Wittsten, Axel; Rehn, Matilda; Bryder, David; Cammenga, Jörg Published in: Blood DOI: 1.1182/blood-14-4-56765
More informationPublished Ahead of Print on June 10, 2013, as doi: /haematol Copyright 2013 Ferrata Storti Foundation.
Published Ahead of Print on June 10, 2013, as doi:10.3324/haematol.2013.088377. Copyright 2013 Ferrata Storti Foundation. Early Release Paper First line treatment with rituximab- Hyper-CVAD alternating
More informationPD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma
Published Ahead of Print on July 19, 2018, as doi:10.3324/haematol.2018.197194. Copyright 2018 Ferrata Storti Foundation. PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict
More informationJanuary NCCTG Protocol No: N0927 Opened: September 3, 2009
January 2011 0915-1 RTOG Protocol No: 0915 Protocol Status: NCCTG Protocol No: N0927 Opened: September 3, 2009 Title: A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT)
More informationA multi-state model for the prognosis of non-mild acute pancreatitis
A multi-state model for the prognosis of non-mild acute pancreatitis Lore Zumeta Olaskoaga 1, Felix Zubia Olaskoaga 2, Guadalupe Gómez Melis 1 1 Universitat Politècnica de Catalunya 2 Intensive Care Unit,
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationJefferies Gene Editing/Therapy Summit Matthew Kapusta, Interim Chief Executive Officer OCTOBER 11, 2016
Jefferies Gene Editing/Therapy Summit Matthew Kapusta, Interim Chief Executive Officer OCTOBER 11, 2016 This presentation contains forward-looking statements. All statements other than statements of historical
More informationLecture 7 Time-dependent Covariates in Cox Regression
Lecture 7 Time-dependent Covariates in Cox Regression So far, we ve been considering the following Cox PH model: λ(t Z) = λ 0 (t) exp(β Z) = λ 0 (t) exp( β j Z j ) where β j is the parameter for the the
More informationIndividualized Treatment Effects with Censored Data via Nonparametric Accelerated Failure Time Models
Individualized Treatment Effects with Censored Data via Nonparametric Accelerated Failure Time Models Nicholas C. Henderson Thomas A. Louis Gary Rosner Ravi Varadhan Johns Hopkins University July 31, 2018
More informationPublished Ahead of Print on April 19, 2018, as doi: /haematol Copyright 2018 Ferrata Storti Foundation.
Published Ahead of Print on April 19, 2018, as doi:10.3324/haematol.2018.189837. Copyright 2018 Ferrata Storti Foundation. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic
More informationMulti-state Models: An Overview
Multi-state Models: An Overview Andrew Titman Lancaster University 14 April 2016 Overview Introduction to multi-state modelling Examples of applications Continuously observed processes Intermittently observed
More informationMoveDMD: Phase 1/2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy
MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy Richard Finkel, MD 1, ; Krista Vandenborne, PT, PhD. 2, H Lee Sweeney, PhD. 2,
More informationof 2-Phenoxyethanol in B6D2F1 Mice
Summary of Drinking Water Carcinogenicity Study of 2-Phenoxyethanol in B6D2F1 Mice June 2007 Japan Bioassay Research Center Japan Industrial Safety and Health Association PREFACE The tests were contracted
More informationMulti-state models: prediction
Department of Medical Statistics and Bioinformatics Leiden University Medical Center Course on advanced survival analysis, Copenhagen Outline Prediction Theory Aalen-Johansen Computational aspects Applications
More informationMultistate models in survival and event history analysis
Multistate models in survival and event history analysis Dorota M. Dabrowska UCLA November 8, 2011 Research supported by the grant R01 AI067943 from NIAID. The content is solely the responsibility of the
More informationNSABP PROTOCOL B-39 RTOG PROTOCOL 0413
NSABP PROTOCOL B-39 RTOG PROTOCOL 0413 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
More informationSupplementary Online Content
Supplementary Online Content Sellers MM, Keele LJ, Sharoky CE, Wirtalla C, Bailey EA, Kelz RR. Association of surgical practice patterns and clinical outcomes with surgeon training in university- or nonuniversity-based
More informationDistributed analysis in multi-center studies
Distributed analysis in multi-center studies Sharing of individual-level data across health plans or healthcare delivery systems continues to be challenging due to concerns about loss of patient privacy,
More informationREGRESSION ANALYSIS FOR TIME-TO-EVENT DATA THE PROPORTIONAL HAZARDS (COX) MODEL ST520
REGRESSION ANALYSIS FOR TIME-TO-EVENT DATA THE PROPORTIONAL HAZARDS (COX) MODEL ST520 Department of Statistics North Carolina State University Presented by: Butch Tsiatis, Department of Statistics, NCSU
More informationPK-QT analysis of bedaquiline : Bedaquiline appears to antagonize its main metabolite s QTcF interval prolonging effect
PK-QT analysis of bedaquiline : Bedaquiline appears to antagonize its main metabolite s QTcF interval prolonging effect Lénaïg Tanneau 1, Elin Svensson 1,2, Stefaan Rossenu 3, Mats Karlsson 1 1 Department
More informationClinical performance of Swelab Lumi 5-part hematology analyzer
Clinical performance of Swelab Lumi -part hematology analyzer A complete blood count (CBC) is frequently requested by physicians to obtain information about a patient s blood status, and tests are routinely
More informationTHE EURES WORLD. Handbook
THE EURES WORLD Handbook 01. EURES: general information hz^ deed / W ^ W^ D ^ h E / > ^ hz^ dd hz^ History and objectives, W hz^ deed W ^ W^ D ^ h E / > ^ hz^ d / W^ d h K h d hz^ hz^ d d hz^ d hz^ d >
More informationAnalysis of competing risks data and simulation of data following predened subdistribution hazards
Analysis of competing risks data and simulation of data following predened subdistribution hazards Bernhard Haller Institut für Medizinische Statistik und Epidemiologie Technische Universität München 27.05.2013
More informationDefinitions and examples Simple estimation and testing Regression models Goodness of fit for the Cox model. Recap of Part 1. Per Kragh Andersen
Recap of Part 1 Per Kragh Andersen Section of Biostatistics, University of Copenhagen DSBS Course Survival Analysis in Clinical Trials January 2018 1 / 65 Overview Definitions and examples Simple estimation
More informationPackage threg. August 10, 2015
Package threg August 10, 2015 Title Threshold Regression Version 1.0.3 Date 2015-08-10 Author Tao Xiao Maintainer Tao Xiao Depends R (>= 2.10), survival, Formula Fit a threshold regression
More informationPHA 4123 First Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4123 First Exam Fall 1998 On my honor, I have neither given nor received unauthorized aid in doing this assignment. TYPED KEY Name Question 1. / pts 2. /2 pts 3. / pts 4. / pts. / pts 6. /10 pts 7.
More informationA SIX MONTH OLD GIRL WITH HEMOLYTIC ANEMIA Case study by Jim Perkins, M.D. ( 2009)
A SIX MONTH OLD GIRL WITH HEMOLYTIC ANEMIA Case study by Jim Perkins, M.D. ( 2009) CLINICAL PRESENTATION A six month old girl presented with lethargy after four days of cough, rhinorrhea, and fever, and
More informationMAS3301 / MAS8311 Biostatistics Part II: Survival
MAS3301 / MAS8311 Biostatistics Part II: Survival M. Farrow School of Mathematics and Statistics Newcastle University Semester 2, 2009-10 1 13 The Cox proportional hazards model 13.1 Introduction In the
More informationAnalysis of Longitudinal Data. Patrick J. Heagerty PhD Department of Biostatistics University of Washington
Analysis of Longitudinal Data Patrick J Heagerty PhD Department of Biostatistics University of Washington Auckland 8 Session One Outline Examples of longitudinal data Scientific motivation Opportunities
More informationG-CSF treatment of chemotherapy induced. neutropenia - Online supplement
G-CSF treatment of chemotherapy induced neutropenia - Online supplement Eliezer Shochat and Vered Rom-Kedar Weizmann Institute of Science May 31, 2008 1 The online supplement begins with introducing the
More informationImplementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
Publishe Ahea of Print on September 22, 2016, as oi:10.3324/haematol.2016.147843. Copyright 2016 Ferrata Storti Founation. Implementation of erythroi lineage analysis by flow cytometry in iagnostic moels
More informationStatistics in medicine
Statistics in medicine Lecture 4: and multivariable regression Fatma Shebl, MD, MS, MPH, PhD Assistant Professor Chronic Disease Epidemiology Department Yale School of Public Health Fatma.shebl@yale.edu
More informationNCCTG Status Report for Study N May 2010
Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for dvanced Small Bowel denocarcinoma Purpose of - Primary Goal Study: 1) To assess the
More informationChronic Granulomatous Disease Medical Management
Chronic Granulomatous Disease Medical Management N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t
More informationChapter 4 Fall Notations: t 1 < t 2 < < t D, D unique death times. d j = # deaths at t j = n. Y j = # at risk /alive at t j = n
Bios 323: Applied Survival Analysis Qingxia (Cindy) Chen Chapter 4 Fall 2012 4.2 Estimators of the survival and cumulative hazard functions for RC data Suppose X is a continuous random failure time with
More informationBIOL 51A - Biostatistics 1 1. Lecture 1: Intro to Biostatistics. Smoking: hazardous? FEV (l) Smoke
BIOL 51A - Biostatistics 1 1 Lecture 1: Intro to Biostatistics Smoking: hazardous? FEV (l) 1 2 3 4 5 No Yes Smoke BIOL 51A - Biostatistics 1 2 Box Plot a.k.a box-and-whisker diagram or candlestick chart
More informationExtensions of Cox Model for Non-Proportional Hazards Purpose
PhUSE Annual Conference 2013 Paper SP07 Extensions of Cox Model for Non-Proportional Hazards Purpose Author: Jadwiga Borucka PAREXEL, Warsaw, Poland Brussels 13 th - 16 th October 2013 Presentation Plan
More informationEffects of AG-348, a pyruvate kinase activator, in patients with pyruvate kinase deficiency: Updated results from the DRIVE PK study
S451 Effects of AG-348, a pyruvate kinase activator, in patients with pyruvate kinase deficiency: Updated results from the DRIVE PK study Rachael F Grace* 1, D Mark Layton 2, Frédéric Galactéros 3, Christian
More informationModular Program Report
Modular Program Report Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety
More informationJanuary 2011 NCIC CTG MA.20 (RTOG Endorsed) -1. Opened: December 14, 1999 Closed: February 2, 2007
January 2011 NCIC CTG MA.20 (RTOG Endorsed) -1 NCIC CTG MA.20 (RTOG Endorsed) Protocol Status: Opened: December 14, 1999 Closed: February 2, 2007 Title: A Phase III Study of Regional Radiation Therapy
More informationCatalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma
Published Ahead of Print on October 5, 2017, as doi:10.3324/haematol.2017.174037. Copyright 2017 Ferrata Storti Foundation. Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationTitle: Department: Previous Version(s): Replaces:
Title: Department: Pediatric Massive Transfusion Protocol (MTP) Trauma Services Effective Date: 09/2014 Reviewed: Policy and Protocol Previous Version(s): Replaces: **The reader is cautioned to refer to
More informationADVANCED STATISTICAL ANALYSIS OF EPIDEMIOLOGICAL STUDIES. Cox s regression analysis Time dependent explanatory variables
ADVANCED STATISTICAL ANALYSIS OF EPIDEMIOLOGICAL STUDIES Cox s regression analysis Time dependent explanatory variables Henrik Ravn Bandim Health Project, Statens Serum Institut 4 November 2011 1 / 53
More informationTime-dependent covariates
Time-dependent covariates Rasmus Waagepetersen November 5, 2018 1 / 10 Time-dependent covariates Our excursion into the realm of counting process and martingales showed that it poses no problems to introduce
More informationOptimal Treatment Regimes for Survival Endpoints from a Classification Perspective. Anastasios (Butch) Tsiatis and Xiaofei Bai
Optimal Treatment Regimes for Survival Endpoints from a Classification Perspective Anastasios (Butch) Tsiatis and Xiaofei Bai Department of Statistics North Carolina State University 1/35 Optimal Treatment
More informationPractical: Acid-base balance
Practical: Acid-base balance Definition All the processes inside the body which keep the H+ concentration within normal values. It is a result of the hydro-electrolytic balance and a sum of mechanisms
More informationEast West Acupuncture & Wellness Center, Inc. Patient Intake Form
East West Acupuncture & Wellness Center, Inc. Patient Intake Form Date: / / How did you hear about us? ( )Ad ( ) Healthcare Referral ( ) Friend/Family Whom may we thank for the referral? Name DOB / / Age
More informationAccepted Manuscript. Comparing different ways of calculating sample size for two independent means: A worked example
Accepted Manuscript Comparing different ways of calculating sample size for two independent means: A worked example Lei Clifton, Jacqueline Birks, David A. Clifton PII: S2451-8654(18)30128-5 DOI: https://doi.org/10.1016/j.conctc.2018.100309
More informationMulticompartment Pharmacokinetic Models. Objectives. Multicompartment Models. 26 July Chapter 30 1
Multicompartment Pharmacokinetic Models Objectives To draw schemes and write differential equations for multicompartment models To recognize and use integrated equations to calculate dosage regimens To
More informationBAYESIAN STATISTICAL ANALYSIS IN A PHASE II DOSE-FINDING TRIAL WITH SURVIVAL ENDPOINT IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
BAYESIAN STATISTICAL ANALYSIS IN A PHASE II DOSE-FINDING TRIAL WITH SURVIVAL ENDPOINT IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA By SHIANSONG LI A dissertation submitted to the School of Public
More informationYou know I m not goin diss you on the internet Cause my mama taught me better than that I m a survivor (What?) I m not goin give up (What?
You know I m not goin diss you on the internet Cause my mama taught me better than that I m a survivor (What?) I m not goin give up (What?) I m not goin stop (What?) I m goin work harder (What?) Sir David
More informationBayesian Nonparametric Accelerated Failure Time Models for Analyzing Heterogeneous Treatment Effects
Bayesian Nonparametric Accelerated Failure Time Models for Analyzing Heterogeneous Treatment Effects Nicholas C. Henderson Thomas A. Louis Gary Rosner Ravi Varadhan Johns Hopkins University September 28,
More informationA2.19. Supplementary Materials for Appendix 2
A2.19 Supplementary Materials for Appendix 2 A2.20 Parameter Ref. Low Ref. High 12 Month 6 Month 3 Month Rabbit ID# B-51 B-71 B-51 B-52 B-53 B-54 B-55 B-56 B-57 B-58 B-59 B-60 B-61 B-62 B-63 B-64 B-65
More informationPhilosophy and Features of the mstate package
Introduction Mathematical theory Practice Discussion Philosophy and Features of the mstate package Liesbeth de Wreede, Hein Putter Department of Medical Statistics and Bioinformatics Leiden University
More information4 Data collection tables, worksheets, and checklists
4 Data collection tables, worksheets, and checklists 1 2 Table 4.1 Contact and data collection schematic for ADAPT (ADAPTDC.Tab) 1 Type of visit/contact Eligibility Enrollment Cognitive assessment Followup
More informationLecture 9. Statistics Survival Analysis. Presented February 23, Dan Gillen Department of Statistics University of California, Irvine
Statistics 255 - Survival Analysis Presented February 23, 2016 Dan Gillen Department of Statistics University of California, Irvine 9.1 Survival analysis involves subjects moving through time Hazard may
More informationAn Overview of Methods for Applying Semi-Markov Processes in Biostatistics.
An Overview of Methods for Applying Semi-Markov Processes in Biostatistics. Charles J. Mode Department of Mathematics and Computer Science Drexel University Philadelphia, PA 19104 Overview of Topics. I.
More informationCHAPTER 3 FEATURE EXTRACTION USING GENETIC ALGORITHM BASED PRINCIPAL COMPONENT ANALYSIS
46 CHAPTER 3 FEATURE EXTRACTION USING GENETIC ALGORITHM BASED PRINCIPAL COMPONENT ANALYSIS 3.1 INTRODUCTION Cardiac beat classification is a key process in the detection of myocardial ischemic episodes
More informationCairns Hospital: Suspected Acute Coronary Syndrome Pathways. DO NOT USE if a non cardiac cause for the chest pain can be diagnosed
Cairns Hospital: Suspected Acute Coronary Syndrome Pathways DO NOT USE if a non cardiac cause for the chest pain can be diagnosed Clinical pathways never replace clinical judgement. Care outlined on this
More informationSupplementary Tables and Figures
Supplementary Tables Supplementary Tables and Figures Supplementary Table 1: Tumor types and samples analyzed. Supplementary Table 2: Genes analyzed here. Supplementary Table 3: Statistically significant
More informationESR1 Allele Frequency. PIK3CA Allele Frequency
Supplementary Figure 1 Distribution of mutant allele frequencies ESR1 Allele Frequency Median allele frequency 0.45% Inset graph 10 20 30 40 50 PIK3CA Allele Frequency Median allele frequency 3.6% Inset
More informationProbability and Probability Distributions. Dr. Mohammed Alahmed
Probability and Probability Distributions 1 Probability and Probability Distributions Usually we want to do more with data than just describing them! We might want to test certain specific inferences about
More informationMASSACHUSETTS INSTITUTE OF TECHNOLOGY
Harvard-MIT Division of Health Sciences and Technology HST.54J: Quantitative Physiology: Organ Transport Systems Instructors: Roger Mark and Jose Venegas MASSACHUSETTS INSTITUTE OF TECHNOLOGY Departments
More informationWhat is statistics? Statistics is the science of: Collecting information. Organizing and summarizing the information collected
What is statistics? Statistics is the science of: Collecting information Organizing and summarizing the information collected Analyzing the information collected in order to draw conclusions Two types
More informationLate thyroid complications in childhood acute leukemia survivors. An L.E.A. study
Published Ahead of Print on March 11, 2016, as doi:10.3324/haematol.2015.140053. Copyright 2016 Ferrata Storti Foundation. Late thyroid complications in childhood acute leukemia survivors. An L.E.A. study
More information